{"name":"Jiangsu HengRui Medicine Co., Ltd.","slug":"jiangsu-hengrui-medicine-co-ltd","ticker":"","exchange":"","domain":"jiangsuhengruimedicine.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-22","label":"Carelizumab Phase 3 readout (NSCLC (Non-small Cell Lung Cancer))","drug":"Carelizumab","drugSlug":"carelizumab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":41,"colorKey":"immunology","drugs":[{"name":"HR17031 injection","genericName":"HR17031 injection","slug":"hr17031-injection","indication":"Solid tumors (specific indications under investigation in phase 3)","status":"phase_3"},{"name":"HRS-8427","genericName":"HRS-8427","slug":"hrs-8427","indication":"Cancer (specific indication under Phase 3 evaluation)","status":"phase_3"},{"name":"Apatinib Mesylate, Gefitinib","genericName":"Apatinib Mesylate, Gefitinib","slug":"apatinib-mesylate-gefitinib","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Fuzuloparib , Abiraterone acetate and Prednisone","genericName":"Fuzuloparib , Abiraterone acetate and Prednisone","slug":"fuzuloparib-abiraterone-acetate-and-prednisone","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency","status":"phase_3"},{"name":"GEMOX","genericName":"GEMOX","slug":"gemox","indication":"Colorectal cancer","status":"phase_2"},{"name":"Irinotecan liposome、5-Fluorouracil、Leucovorin","genericName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","slug":"irinotecan-liposome-5-fluorouracil-leucovorin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","genericName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","slug":"ramucirumab-paclitaxel-docetaxel-irinotecan","indication":"Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"SHR-1209","genericName":"SHR-1209","slug":"shr-1209","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-1314","genericName":"SHR-1314","slug":"shr-1314","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","genericName":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","slug":"shr-1316-carboplatin-etoposide-radiotherapy","indication":"Small cell lung cancer","status":"phase_3"},{"name":"SHR2554 analog tablets; Chidamide","genericName":"SHR2554 analog tablets; Chidamide","slug":"shr2554-analog-tablets-chidamide","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"},{"name":"Apatinib and Etoposide capsule","genericName":"Apatinib and Etoposide capsule","slug":"apatinib-and-etoposide-capsule","indication":"Metastatic gastric cancer","status":"phase_2"},{"name":"Avastin®, paclitaxel, carboplatin","genericName":"Avastin®, paclitaxel, carboplatin","slug":"avastin-paclitaxel-carboplatin","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"BP102, paclitaxel, carboplatin","genericName":"BP102, paclitaxel, carboplatin","slug":"bp102-paclitaxel-carboplatin","indication":"Non-small cell lung cancer (phase 3)","status":"phase_3"},{"name":"Camrelizumab Plus Chemotherapy","genericName":"Camrelizumab Plus Chemotherapy","slug":"camrelizumab-plus-chemotherapy","indication":"Non-small cell lung cancer (NSCLC) in combination with chemotherapy","status":"phase_3"},{"name":"Carboplatin for Injection","genericName":"Carboplatin for Injection","slug":"carboplatin-for-injection","indication":"Ovarian cancer","status":"phase_3"},{"name":"Enzalutamide Soft Capsules","genericName":"Enzalutamide Soft Capsules","slug":"enzalutamide-soft-capsules","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Fluzoparib Combined With Apatinib","genericName":"Fluzoparib Combined With Apatinib","slug":"fluzoparib-combined-with-apatinib","indication":"Advanced solid tumors","status":"phase_2"},{"name":"Fluzoparib; Apatinib","genericName":"Fluzoparib; Apatinib","slug":"fluzoparib-apatinib","indication":"Ovarian cancer (BRCA-mutated or homologous recombination-deficient)","status":"phase_3"},{"name":"HRS-4357 injection","genericName":"HRS-4357 injection","slug":"hrs-4357-injection","indication":"Advanced or metastatic solid tumors (specific indications under investigation in Phase 3)","status":"phase_3"},{"name":"HRS-4642 + AG","genericName":"HRS-4642 + AG","slug":"hrs-4642-ag","indication":"Advanced or metastatic solid tumors (specific indication under phase 3 evaluation)","status":"phase_3"},{"name":"HRS-9231","genericName":"HRS-9231","slug":"hrs-9231","indication":"Solid tumors (specific indications in phase 3 development)","status":"phase_3"},{"name":"INS068 injection","genericName":"INS068 injection","slug":"ins068-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Letrozole or Anastrozole Tablets","genericName":"Letrozole or Anastrozole Tablets","slug":"letrozole-or-anastrozole-tablets","indication":"Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic)","status":"phase_3"},{"name":"Palcebo; Carboplatin; Etoposide；Radiotherapy","genericName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","slug":"palcebo-carboplatin-etoposide-radiotherapy","indication":"Likely small cell lung cancer or other solid tumors (specific indication not provided)","status":"phase_3"},{"name":"Placebo, Trastuzumab, Docetaxel","genericName":"Placebo, Trastuzumab, Docetaxel","slug":"placebo-trastuzumab-docetaxel","indication":"HER2-positive breast cancer (metastatic or early-stage)","status":"phase_3"},{"name":"Placebo、5-Fluorouracil、Leucovorin","genericName":"Placebo、5-Fluorouracil、Leucovorin","slug":"placebo-5-fluorouracil-leucovorin","indication":"Colorectal cancer (adjuvant or metastatic)","status":"phase_3"},{"name":"Pyrotinib in combination with Capecitabine.","genericName":"Pyrotinib in combination with Capecitabine.","slug":"pyrotinib-in-combination-with-capecitabine","indication":"Metastatic HER2-positive breast cancer","status":"phase_3"},{"name":"Pyrotinib, Trastuzumab, Docetaxel","genericName":"Pyrotinib, Trastuzumab, Docetaxel","slug":"pyrotinib-trastuzumab-docetaxel","indication":"Advanced or metastatic breast cancer with HER2 overexpression","status":"phase_3"},{"name":"Rezvilutamide Tablets","genericName":"Rezvilutamide Tablets","slug":"rezvilutamide-tablets","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Rivoceranib (Apatinib)","genericName":"Rivoceranib (Apatinib)","slug":"rivoceranib-apatinib","indication":"Metastatic gastric cancer, Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"SHR-1316、Chemotherapeutic","genericName":"SHR-1316、Chemotherapeutic","slug":"shr-1316-chemotherapeutic","indication":"Solid tumors (specific indications under phase 3 evaluation)","status":"phase_3"},{"name":"SHR-A1811","genericName":"SHR-A1811","slug":"shr-a1811","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-A1811 Injection ； Pertuzumab Injection","genericName":"SHR-A1811 Injection ； Pertuzumab Injection","slug":"shr-a1811-injection-pertuzumab-injection","indication":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","status":"phase_3"},{"name":"SHR0302","genericName":"SHR0302","slug":"shr0302","indication":"Advanced solid tumors","status":"phase_3"},{"name":"SHR2554; Chidamide analog tablets","genericName":"SHR2554; Chidamide analog tablets","slug":"shr2554-chidamide-analog-tablets","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"},{"name":"TACE+Camrelizumab+Apatinib mesylate","genericName":"TACE+Camrelizumab+Apatinib mesylate","slug":"tace-camrelizumab-apatinib-mesylate","indication":"Hepatocellular carcinoma (HCC), unresectable or advanced stage","status":"phase_3"},{"name":"camrelizumab； famitinib malate","genericName":"camrelizumab； famitinib malate","slug":"camrelizumab-famitinib-malate","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"long-acting Octreotide.","genericName":"long-acting Octreotide.","slug":"long-acting-octreotide","indication":"Acromegaly","status":"phase_3"},{"name":"nab-paclitaxel; gemcitabine","genericName":"nab-paclitaxel; gemcitabine","slug":"nab-paclitaxel-gemcitabine","indication":"Pancreatic cancer","status":"phase_3"},{"name":"placebo+chemotherapy","genericName":"placebo+chemotherapy","slug":"placebo-chemotherapy","indication":"Metastatic breast cancer, Metastatic non-small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":38,"colorKey":"oncology","drugs":[{"name":"Digoxin tablet","genericName":"Digoxin tablet","slug":"digoxin-tablet","indication":"Other","status":"marketed"},{"name":"ApatinibTablets","genericName":"ApatinibTablets","slug":"apatinibtablets","indication":"Other","status":"marketed"},{"name":"Drug: Pegylated rhG-CSF: 100µg/kg","genericName":"Drug: Pegylated rhG-CSF: 100µg/kg","slug":"drug-pegylated-rhg-csf-100-g-kg","indication":"Chemotherapy-induced neutropenia (CIN)","status":"phase_3"},{"name":"FOLFOX4","genericName":"FOLFOX4","slug":"folfox4","indication":"Other","status":"marketed"},{"name":"HR021618","genericName":"HR021618","slug":"hr021618","indication":"Other","status":"phase_2"},{"name":"HRS-1738 Injection","genericName":"HRS-1738 Injection","slug":"hrs-1738-injection","indication":"Other","status":"phase_1"},{"name":"HRS-6209 in Combination with Letrozole","genericName":"HRS-6209 in Combination with Letrozole","slug":"hrs-6209-in-combination-with-letrozole","indication":"Other","status":"phase_1"},{"name":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","genericName":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","slug":"hetrombopag-olamine-tablet-ciclosporin-soft-capsule","indication":"Other","status":"phase_1"},{"name":"SHR3824","genericName":"SHR3824","slug":"shr3824","indication":"Unknown","status":"phase_3"},{"name":"SHR7280；Ganirelix Acetate Injection simulant","genericName":"SHR7280；Ganirelix Acetate Injection simulant","slug":"shr7280-ganirelix-acetate-injection-simulant","indication":"Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology","status":"phase_3"},{"name":"Carelizumab","genericName":"Carelizumab","slug":"carelizumab","indication":"Other","status":"discontinued"},{"name":"Cipatinib","genericName":"Cipatinib","slug":"cipatinib","indication":"Other","status":"discontinued"},{"name":"FH-006 ; SHR-1316 ; BP102","genericName":"FH-006 ; SHR-1316 ; BP102","slug":"fh-006-shr-1316-bp102","indication":"unknown","status":"phase_2"},{"name":"Fluconazole、Famitinib","genericName":"Fluconazole、Famitinib","slug":"fluconazole-famitinib","indication":"Other","status":"phase_1"},{"name":"HR020602 injection","genericName":"HR020602 injection","slug":"hr020602-injection","indication":"Other","status":"phase_2"},{"name":"HR070803","genericName":"HR070803","slug":"hr070803","indication":"Other","status":"phase_2"},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection","genericName":"HR17031 injection ；INS068 injection；SHR20004 injection","slug":"hr17031-injection-ins068-injection-shr20004-injection","indication":"Other","status":"phase_1"},{"name":"HR19042 Capsules","genericName":"HR19042 Capsules","slug":"hr19042-capsules","indication":"Other","status":"phase_2"},{"name":"HR19042 capsule","genericName":"HR19042 capsule","slug":"hr19042-capsule","indication":"Other","status":"phase_1"},{"name":"HRS-1167","genericName":"HRS-1167","slug":"hrs-1167","indication":"Other","status":"phase_2"},{"name":"HRS-4508 tablet","genericName":"HRS-4508 tablet","slug":"hrs-4508-tablet","indication":"Unknown","status":"phase_2"},{"name":"HRS-5041 tablets","genericName":"HRS-5041 tablets","slug":"hrs-5041-tablets","indication":"Other","status":"phase_1"},{"name":"HRS-9190; under Inhalational Anesthesia","genericName":"HRS-9190; under Inhalational Anesthesia","slug":"hrs-9190-under-inhalational-anesthesia","indication":"Other","status":"phase_2"},{"name":"HRS4800 tablets","genericName":"HRS4800 tablets","slug":"hrs4800-tablets","indication":"Other","status":"phase_2"},{"name":"HS-10296 po","genericName":"HS-10296 po","slug":"hs-10296-po","indication":"Other","status":"phase_2"},{"name":"IvabRadine hemisulfate Sustained-release Tablets","genericName":"IvabRadine hemisulfate Sustained-release Tablets","slug":"ivabradine-hemisulfate-sustained-release-tablets","indication":"Other","status":"phase_2"},{"name":"Morhpine PCA","genericName":"Morhpine PCA","slug":"morhpine-pca","indication":"Other","status":"phase_2"},{"name":"Nifedipine GTIS","genericName":"Nifedipine GTIS","slug":"nifedipine-gtis","indication":"Other","status":"phase_1"},{"name":"Pegylated rhG-CSF: 100µg/kg","genericName":"Pegylated rhG-CSF: 100µg/kg","slug":"pegylated-rhg-csf-100-g-kg","indication":"Chemotherapy-induced neutropenia (CIN)","status":"phase_3"},{"name":"Placebo+Standard Therapy","genericName":"Placebo+Standard Therapy","slug":"placebo-standard-therapy","indication":"Various conditions","status":"phase_3"},{"name":"Placebo、Chemotherapeutic","genericName":"Placebo、Chemotherapeutic","slug":"placebo-chemotherapeutic","indication":"Control arm in chemotherapy clinical trial (specific indication unknown)","status":"phase_3"},{"name":"RSS0343 Tabella","genericName":"RSS0343 Tabella","slug":"rss0343-tabella","indication":"Other","status":"phase_2"},{"name":"Remimazolam Tosilate for Injection","genericName":"Remimazolam Tosilate for Injection","slug":"remimazolam-tosilate-for-injection","indication":"Procedural sedation and anesthesia induction","status":"marketed"},{"name":"SHR-A1811 & Fulvestrant","genericName":"SHR-A1811 & Fulvestrant","slug":"shr-a1811-fulvestrant","indication":"Other","status":"phase_1"},{"name":"SHR2554 Tablets","genericName":"SHR2554 Tablets","slug":"shr2554-tablets","indication":"Other","status":"phase_2"},{"name":"SHR4640","genericName":"SHR4640","slug":"shr4640","indication":"Other","status":"phase_3"},{"name":"SHR7280 simulant； Ganirelix Acetate Injection","genericName":"SHR7280 simulant； Ganirelix Acetate Injection","slug":"shr7280-simulant-ganirelix-acetate-injection","indication":"Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)","status":"phase_3"},{"name":"SP2086","genericName":"SP2086","slug":"sp2086","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Noiiglutide Injection","genericName":"Noiiglutide Injection","slug":"noiiglutide-injection","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"SHR8554 Injection","genericName":"SHR8554 Injection","slug":"shr8554-injection","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"Insulin Degludec Injection","genericName":"Insulin Degludec Injection","slug":"insulin-degludec-injection","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Retagliptin, Henagliflozein, metformin XR","genericName":"Retagliptin, Henagliflozein, metformin XR","slug":"retagliptin-henagliflozein-metformin-xr","indication":"Treatment of type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"Sustained-release Metoprolol Succinate","genericName":"Sustained-release Metoprolol Succinate","slug":"sustained-release-metoprolol-succinate","indication":"Hypertension","status":"phase_3"},{"name":"SHR8008 capsule","genericName":"SHR8008 capsule","slug":"shr8008-capsule","indication":"Hypertension","status":"phase_3"},{"name":"SHR6390 Tablets","genericName":"SHR6390 Tablets","slug":"shr6390-tablets","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"SHR8028 eye drops","genericName":"SHR8028 eye drops","slug":"shr8028-eye-drops","indication":"Open-angle glaucoma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"Herombopag tablets","genericName":"Herombopag tablets","slug":"herombopag-tablets","indication":"Thrombocytopenia in patients with chronic liver disease","status":"phase_3"},{"name":"Fluconazole capsule","genericName":"Fluconazole capsule","slug":"fluconazole-capsule","indication":"Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)","status":"phase_3"},{"name":"Hetrombopag Olamine+Standard Therapy","genericName":"Hetrombopag Olamine+Standard Therapy","slug":"hetrombopag-olamine-standard-therapy","indication":"Immune thrombocytopenia (ITP)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"SHR8058 eye drops","genericName":"SHR8058 eye drops","slug":"shr8058-eye-drops","indication":"Dry eye disease (DED) with neuropathic pain component","status":"phase_3"},{"name":"Pregabalin Release Tablets","genericName":"Pregabalin Release Tablets","slug":"pregabalin-release-tablets","indication":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"metabolic","drugs":[{"name":"Vehicle eye drops.","genericName":"Vehicle eye drops.","slug":"vehicle-eye-drops","indication":"Dry eye syndrome","status":"phase_3"},{"name":"saline eye drops.","genericName":"saline eye drops.","slug":"saline-eye-drops","indication":"Dry eye syndrome","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Imipenem and Cilastatin Sodium","genericName":"Imipenem and Cilastatin Sodium","slug":"imipenem-and-cilastatin-sodium","indication":"Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia","status":"marketed"}]}],"pipeline":[{"name":"Digoxin tablet","genericName":"Digoxin tablet","slug":"digoxin-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ApatinibTablets","genericName":"ApatinibTablets","slug":"apatinibtablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR17031 injection","genericName":"HR17031 injection","slug":"hr17031-injection","phase":"phase_3","mechanism":"HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.","indications":["Solid tumors (specific indications under investigation in phase 3)"],"catalyst":""},{"name":"HRS-8427","genericName":"HRS-8427","slug":"hrs-8427","phase":"phase_3","mechanism":"HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.","indications":["Cancer (specific indication under Phase 3 evaluation)"],"catalyst":""},{"name":"Noiiglutide Injection","genericName":"Noiiglutide Injection","slug":"noiiglutide-injection","phase":"phase_3","mechanism":"Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Sustained-release Metoprolol Succinate","genericName":"Sustained-release Metoprolol Succinate","slug":"sustained-release-metoprolol-succinate","phase":"phase_3","mechanism":"Metoprolol succinate is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and slowing the heart rate and reducing its workload.","indications":["Hypertension","Angina pectoris","Heart failure","Atrial fibrillation for rate control"],"catalyst":""},{"name":"Apatinib Mesylate, Gefitinib","genericName":"Apatinib Mesylate, Gefitinib","slug":"apatinib-mesylate-gefitinib","phase":"phase_1","mechanism":"Tyrosine kinase inhibitor of VEGFR-2 and c-KIT","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Drug: Pegylated rhG-CSF: 100µg/kg","genericName":"Drug: Pegylated rhG-CSF: 100µg/kg","slug":"drug-pegylated-rhg-csf-100-g-kg","phase":"phase_3","mechanism":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN)","Severe congenital neutropenia","Idiopathic or cyclic neutropenia"],"catalyst":""},{"name":"FOLFOX4","genericName":"FOLFOX4","slug":"folfox4","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fuzuloparib , Abiraterone acetate and Prednisone","genericName":"Fuzuloparib , Abiraterone acetate and Prednisone","slug":"fuzuloparib-abiraterone-acetate-and-prednisone","phase":"phase_3","mechanism":"This combination uses fuzuloparib (a PARP inhibitor) to block DNA repair, combined with abiraterone acetate and prednisone to suppress androgen production and signaling in castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair deficiency"],"catalyst":""},{"name":"GEMOX","genericName":"GEMOX","slug":"gemox","phase":"phase_2","mechanism":"Gemcitabine and oxaliplatin combination chemotherapy","indications":["Colorectal cancer"],"catalyst":""},{"name":"HR021618","genericName":"HR021618","slug":"hr021618","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-1738 Injection","genericName":"HRS-1738 Injection","slug":"hrs-1738-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-6209 in Combination with Letrozole","genericName":"HRS-6209 in Combination with Letrozole","slug":"hrs-6209-in-combination-with-letrozole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Herombopag tablets","genericName":"Herombopag tablets","slug":"herombopag-tablets","phase":"phase_3","mechanism":"Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells.","indications":["Thrombocytopenia in patients with chronic liver disease","Immune thrombocytopenia (ITP)"],"catalyst":""},{"name":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","genericName":"Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule","slug":"hetrombopag-olamine-tablet-ciclosporin-soft-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Imipenem and Cilastatin Sodium","genericName":"Imipenem and Cilastatin Sodium","slug":"imipenem-and-cilastatin-sodium","phase":"marketed","mechanism":"Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I.","indications":["Serious bacterial infections including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, and septicemia","Polymicrobial infections and infections caused by gram-positive and gram-negative aerobic and anaerobic bacteria"],"catalyst":""},{"name":"Irinotecan liposome、5-Fluorouracil、Leucovorin","genericName":"Irinotecan liposome、5-Fluorouracil、Leucovorin","slug":"irinotecan-liposome-5-fluorouracil-leucovorin","phase":"phase_3","mechanism":"This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells.","indications":["Metastatic colorectal cancer","Pancreatic cancer (in development)"],"catalyst":""},{"name":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","genericName":"Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan","slug":"ramucirumab-paclitaxel-docetaxel-irinotecan","phase":"phase_3","mechanism":"This is a combination regimen pairing ramucirumab (a VEGF receptor 2 inhibitor) with chemotherapy agents (paclitaxel, docetaxel, or irinotecan) to block tumor angiogenesis while simultaneously attacking cancer cells.","indications":["Advanced gastric cancer or gastroesophageal junction cancer (in combination with chemotherapy)","Non-small cell lung cancer (in combination with chemotherapy)","Colorectal cancer (in combination with chemotherapy)"],"catalyst":""},{"name":"SHR-1209","genericName":"SHR-1209","slug":"shr-1209","phase":"phase_3","mechanism":"SHR-1209 is a humanized monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7-1) to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"SHR-1314","genericName":"SHR-1314","slug":"shr-1314","phase":"phase_3","mechanism":"SHR-1314 is a small molecule targeting the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","genericName":"SHR-1316; Carboplatin; Etoposide；Radiotherapy","slug":"shr-1316-carboplatin-etoposide-radiotherapy","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell growth and inducing apoptosis.","indications":["Small cell lung cancer","Non-small cell lung cancer","Ovarian cancer","Testicular cancer","Other cancers"],"catalyst":""},{"name":"SHR2554 analog tablets; Chidamide","genericName":"SHR2554 analog tablets; Chidamide","slug":"shr2554-analog-tablets-chidamide","phase":"phase_3","mechanism":"Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.","indications":["Relapsed or refractory peripheral T-cell lymphoma","Relapsed or refractory cutaneous T-cell lymphoma"],"catalyst":""},{"name":"SHR3824","genericName":"SHR3824","slug":"shr3824","phase":"phase_3","mechanism":"SHR3824 is a small molecule targeting the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"SHR7280；Ganirelix Acetate Injection simulant","genericName":"SHR7280；Ganirelix Acetate Injection simulant","slug":"shr7280-ganirelix-acetate-injection-simulant","phase":"phase_3","mechanism":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","indications":["Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology"],"catalyst":""},{"name":"SHR8008 capsule","genericName":"SHR8008 capsule","slug":"shr8008-capsule","phase":"phase_3","mechanism":"SHR8008 capsule is a small molecule drug that targets the molecular target.","indications":["Hypertension"],"catalyst":""},{"name":"SHR8058 eye drops","genericName":"SHR8058 eye drops","slug":"shr8058-eye-drops","phase":"phase_3","mechanism":"SHR8058 is a selective TRPM8 channel antagonist that reduces ocular surface pain and irritation by blocking cold-sensitive ion channels in the eye.","indications":["Dry eye disease (DED) with neuropathic pain component"],"catalyst":""},{"name":"SHR8554 Injection","genericName":"SHR8554 Injection","slug":"shr8554-injection","phase":"phase_3","mechanism":"SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Vehicle eye drops.","genericName":"Vehicle eye drops.","slug":"vehicle-eye-drops","phase":"phase_3","mechanism":"Vehicle eye drops serve as a placebo or control treatment in ophthalmic clinical trials.","indications":["Dry eye syndrome","Conjunctivitis"],"catalyst":""},{"name":"Apatinib and Etoposide capsule","genericName":"Apatinib and Etoposide capsule","slug":"apatinib-and-etoposide-capsule","phase":"phase_2","mechanism":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription.","indications":["Metastatic gastric cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Avastin®, paclitaxel, carboplatin","genericName":"Avastin®, paclitaxel, carboplatin","slug":"avastin-paclitaxel-carboplatin","phase":"phase_3","mechanism":"This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells.","indications":["Advanced or metastatic non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"BP102, paclitaxel, carboplatin","genericName":"BP102, paclitaxel, carboplatin","slug":"bp102-paclitaxel-carboplatin","phase":"phase_3","mechanism":"BP102 is a nanoparticle albumin-bound paclitaxel combined with carboplatin chemotherapy that disrupts microtubule dynamics and induces DNA crosslinking to kill cancer cells.","indications":["Non-small cell lung cancer (phase 3)","Potentially other solid tumors (under investigation)"],"catalyst":""},{"name":"Camrelizumab Plus Chemotherapy","genericName":"Camrelizumab Plus Chemotherapy","slug":"camrelizumab-plus-chemotherapy","phase":"phase_3","mechanism":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer (NSCLC) in combination with chemotherapy","Nasopharyngeal carcinoma in combination with chemotherapy","Esophageal squamous cell carcinoma in combination with chemotherapy"],"catalyst":""},{"name":"Carboplatin for Injection","genericName":"Carboplatin for Injection","slug":"carboplatin-for-injection","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis.","indications":["Ovarian cancer","Lung cancer","Breast cancer","Head and neck cancer","Testicular cancer"],"catalyst":""},{"name":"Carelizumab","genericName":"Carelizumab","slug":"carelizumab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cipatinib","genericName":"Cipatinib","slug":"cipatinib","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Enzalutamide Soft Capsules","genericName":"Enzalutamide Soft Capsules","slug":"enzalutamide-soft-capsules","phase":"phase_3","mechanism":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","Non-metastatic castration-resistant prostate cancer (nmCRPC)","Metastatic castration-sensitive prostate cancer (mCSPC)"],"catalyst":""},{"name":"FH-006 ; SHR-1316 ; BP102","genericName":"FH-006 ; SHR-1316 ; BP102","slug":"fh-006-shr-1316-bp102","phase":"phase_2","mechanism":"FH-006 is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"Fluconazole capsule","genericName":"Fluconazole capsule","slug":"fluconazole-capsule","phase":"phase_3","mechanism":"Fluconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Candidiasis (oropharyngeal, esophageal, vaginal, and systemic)","Cryptococcal meningitis","Fungal prophylaxis in immunocompromised patients","Other invasive fungal infections"],"catalyst":""},{"name":"Fluconazole、Famitinib","genericName":"Fluconazole、Famitinib","slug":"fluconazole-famitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fluzoparib Combined With Apatinib","genericName":"Fluzoparib Combined With Apatinib","slug":"fluzoparib-combined-with-apatinib","phase":"phase_2","mechanism":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity.","indications":["Advanced solid tumors"],"catalyst":""},{"name":"Fluzoparib; Apatinib","genericName":"Fluzoparib; Apatinib","slug":"fluzoparib-apatinib","phase":"phase_3","mechanism":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a tyrosine kinase inhibitor targeting VEGFR2, together enhancing anti-tumor effects through synthetic lethality and anti-angiogenesis.","indications":["Ovarian cancer (BRCA-mutated or homologous recombination-deficient)","Gastric cancer","Other solid tumors in phase 3 evaluation"],"catalyst":""},{"name":"HR020602 injection","genericName":"HR020602 injection","slug":"hr020602-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR070803","genericName":"HR070803","slug":"hr070803","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR17031 injection ；INS068 injection；SHR20004 injection","genericName":"HR17031 injection ；INS068 injection；SHR20004 injection","slug":"hr17031-injection-ins068-injection-shr20004-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR19042 Capsules","genericName":"HR19042 Capsules","slug":"hr19042-capsules","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HR19042 capsule","genericName":"HR19042 capsule","slug":"hr19042-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-1167","genericName":"HRS-1167","slug":"hrs-1167","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-4357 injection","genericName":"HRS-4357 injection","slug":"hrs-4357-injection","phase":"phase_3","mechanism":"HRS-4357 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.","indications":["Advanced or metastatic solid tumors (specific indications under investigation in Phase 3)"],"catalyst":""},{"name":"HRS-4508 tablet","genericName":"HRS-4508 tablet","slug":"hrs-4508-tablet","phase":"phase_2","mechanism":"HRS-4508 tablet is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"HRS-4642 + AG","genericName":"HRS-4642 + AG","slug":"hrs-4642-ag","phase":"phase_3","mechanism":"HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth.","indications":["Advanced or metastatic solid tumors (specific indication under phase 3 evaluation)"],"catalyst":""},{"name":"HRS-5041 tablets","genericName":"HRS-5041 tablets","slug":"hrs-5041-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9190; under Inhalational Anesthesia","genericName":"HRS-9190; under Inhalational Anesthesia","slug":"hrs-9190-under-inhalational-anesthesia","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9231","genericName":"HRS-9231","slug":"hrs-9231","phase":"phase_3","mechanism":"HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis.","indications":["Solid tumors (specific indications in phase 3 development)"],"catalyst":""},{"name":"HRS4800 tablets","genericName":"HRS4800 tablets","slug":"hrs4800-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10296 po","genericName":"HS-10296 po","slug":"hs-10296-po","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hetrombopag Olamine+Standard Therapy","genericName":"Hetrombopag Olamine+Standard Therapy","slug":"hetrombopag-olamine-standard-therapy","phase":"phase_3","mechanism":"Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.","indications":["Immune thrombocytopenia (ITP)","Thrombocytopenia in patients with chronic hepatitis C"],"catalyst":""},{"name":"INS068 injection","genericName":"INS068 injection","slug":"ins068-injection","phase":"phase_3","mechanism":"INS068 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Insulin Degludec Injection","genericName":"Insulin Degludec Injection","slug":"insulin-degludec-injection","phase":"phase_3","mechanism":"Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"IvabRadine hemisulfate Sustained-release Tablets","genericName":"IvabRadine hemisulfate Sustained-release Tablets","slug":"ivabradine-hemisulfate-sustained-release-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Letrozole or Anastrozole Tablets","genericName":"Letrozole or Anastrozole Tablets","slug":"letrozole-or-anastrozole-tablets","phase":"phase_3","mechanism":"Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic)","Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"],"catalyst":""},{"name":"Morhpine PCA","genericName":"Morhpine PCA","slug":"morhpine-pca","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nifedipine GTIS","genericName":"Nifedipine GTIS","slug":"nifedipine-gtis","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Palcebo; Carboplatin; Etoposide；Radiotherapy","genericName":"Palcebo; Carboplatin; Etoposide；Radiotherapy","slug":"palcebo-carboplatin-etoposide-radiotherapy","phase":"phase_3","mechanism":"This is a combination regimen using carboplatin and etoposide chemotherapy plus radiotherapy to kill cancer cells through DNA damage and cell cycle disruption, with placebo as a control arm.","indications":["Likely small cell lung cancer or other solid tumors (specific indication not provided)"],"catalyst":""},{"name":"Pegylated rhG-CSF: 100µg/kg","genericName":"Pegylated rhG-CSF: 100µg/kg","slug":"pegylated-rhg-csf-100-g-kg","phase":"phase_3","mechanism":"Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.","indications":["Chemotherapy-induced neutropenia (CIN)","Severe congenital neutropenia","Idiopathic or cyclic neutropenia"],"catalyst":""},{"name":"Placebo+Standard Therapy","genericName":"Placebo+Standard Therapy","slug":"placebo-standard-therapy","phase":"phase_3","mechanism":"This drug is a placebo in combination with standard therapy.","indications":["Various conditions"],"catalyst":""},{"name":"Placebo, Trastuzumab, Docetaxel","genericName":"Placebo, Trastuzumab, Docetaxel","slug":"placebo-trastuzumab-docetaxel","phase":"phase_3","mechanism":"This combination uses trastuzumab to block HER2 signaling in cancer cells while docetaxel disrupts microtubule dynamics to inhibit cell division, with placebo as a control arm.","indications":["HER2-positive breast cancer (metastatic or early-stage)","HER2-positive gastric cancer"],"catalyst":""},{"name":"Placebo、5-Fluorouracil、Leucovorin","genericName":"Placebo、5-Fluorouracil、Leucovorin","slug":"placebo-5-fluorouracil-leucovorin","phase":"phase_3","mechanism":"5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex.","indications":["Colorectal cancer (adjuvant or metastatic)","Gastric cancer","Breast cancer","Pancreatic cancer"],"catalyst":""},{"name":"Placebo、Chemotherapeutic","genericName":"Placebo、Chemotherapeutic","slug":"placebo-chemotherapeutic","phase":"phase_3","mechanism":"This is a placebo control used in chemotherapy clinical trials to establish efficacy of an active chemotherapeutic agent.","indications":["Control arm in chemotherapy clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Pregabalin Release Tablets","genericName":"Pregabalin Release Tablets","slug":"pregabalin-release-tablets","phase":"phase_3","mechanism":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","indications":["Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain)","Partial-onset seizures (adjunctive therapy)","Generalized anxiety disorder","Fibromyalgia"],"catalyst":""},{"name":"Pyrotinib in combination with Capecitabine.","genericName":"Pyrotinib in combination with Capecitabine.","slug":"pyrotinib-in-combination-with-capecitabine","phase":"phase_3","mechanism":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, and when combined with Capecitabine, it is used to treat HER2-positive breast cancer.","indications":["Metastatic HER2-positive breast cancer"],"catalyst":""},{"name":"Pyrotinib, Trastuzumab, Docetaxel","genericName":"Pyrotinib, Trastuzumab, Docetaxel","slug":"pyrotinib-trastuzumab-docetaxel","phase":"phase_3","mechanism":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly.","indications":["Advanced or metastatic breast cancer with HER2 overexpression","Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression"],"catalyst":""},{"name":"RSS0343 Tabella","genericName":"RSS0343 Tabella","slug":"rss0343-tabella","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Remimazolam Tosilate for Injection","genericName":"Remimazolam Tosilate for Injection","slug":"remimazolam-tosilate-for-injection","phase":"marketed","mechanism":"Remimazolam is a benzodiazepine that enhances GABAergic neurotransmission by binding to GABA-A receptors, producing sedation and anxiolysis.","indications":["Procedural sedation and anesthesia induction","Sedation in intensive care units"],"catalyst":""},{"name":"Retagliptin, Henagliflozein, metformin XR","genericName":"Retagliptin, Henagliflozein, metformin XR","slug":"retagliptin-henagliflozein-metformin-xr","phase":"phase_3","mechanism":"Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Rezvilutamide Tablets","genericName":"Rezvilutamide Tablets","slug":"rezvilutamide-tablets","phase":"phase_3","mechanism":"Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"Rivoceranib (Apatinib)","genericName":"Rivoceranib (Apatinib)","slug":"rivoceranib-apatinib","phase":"phase_3","mechanism":"Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2).","indications":["Metastatic gastric cancer, Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"SHR-1316、Chemotherapeutic","genericName":"SHR-1316、Chemotherapeutic","slug":"shr-1316-chemotherapeutic","phase":"phase_3","mechanism":"SHR-1316 is a chemotherapeutic agent that inhibits tubulin polymerization to disrupt microtubule dynamics and induce cancer cell death.","indications":["Solid tumors (specific indications under phase 3 evaluation)"],"catalyst":""},{"name":"SHR-A1811","genericName":"SHR-A1811","slug":"shr-a1811","phase":"phase_3","mechanism":"SHR-A1811 is a small molecule targeting the molecular target.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"SHR-A1811 & Fulvestrant","genericName":"SHR-A1811 & Fulvestrant","slug":"shr-a1811-fulvestrant","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR-A1811 Injection ； Pertuzumab Injection","genericName":"SHR-A1811 Injection ； Pertuzumab Injection","slug":"shr-a1811-injection-pertuzumab-injection","phase":"phase_3","mechanism":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling.","indications":["HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"SHR0302","genericName":"SHR0302","slug":"shr0302","phase":"phase_3","mechanism":"SHR0302 is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Advanced solid tumors","Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"SHR2554 Tablets","genericName":"SHR2554 Tablets","slug":"shr2554-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR2554; Chidamide analog tablets","genericName":"SHR2554; Chidamide analog tablets","slug":"shr2554-chidamide-analog-tablets","phase":"phase_3","mechanism":"Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression.","indications":["Relapsed or refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"SHR4640","genericName":"SHR4640","slug":"shr4640","phase":"phase_3","mechanism":"SHR4640 is a small-molecule inhibitor that targets and blocks specific kinase pathways involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"SHR6390 Tablets","genericName":"SHR6390 Tablets","slug":"shr6390-tablets","phase":"phase_3","mechanism":"SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"SHR7280 simulant； Ganirelix Acetate Injection","genericName":"SHR7280 simulant； Ganirelix Acetate Injection","slug":"shr7280-simulant-ganirelix-acetate-injection","phase":"phase_3","mechanism":"Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","indications":["Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)"],"catalyst":""},{"name":"SHR8028 eye drops","genericName":"SHR8028 eye drops","slug":"shr8028-eye-drops","phase":"phase_3","mechanism":"SHR8028 is a selective rho-associated protein kinase (ROCK) inhibitor administered as eye drops to reduce intraocular pressure in glaucoma.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"SP2086","genericName":"SP2086","slug":"sp2086","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TACE+Camrelizumab+Apatinib mesylate","genericName":"TACE+Camrelizumab+Apatinib mesylate","slug":"tace-camrelizumab-apatinib-mesylate","phase":"phase_3","mechanism":"This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis.","indications":["Hepatocellular carcinoma (HCC), unresectable or advanced stage"],"catalyst":""},{"name":"camrelizumab； famitinib malate","genericName":"camrelizumab； famitinib malate","slug":"camrelizumab-famitinib-malate","phase":"phase_3","mechanism":"Camrelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immune response.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Multiple myeloma"],"catalyst":""},{"name":"long-acting Octreotide.","genericName":"long-acting Octreotide.","slug":"long-acting-octreotide","phase":"phase_3","mechanism":"Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.","indications":["Acromegaly","Neuroendocrine tumors (carcinoid syndrome, VIPomas)","Gastroenteropancreatic neuroendocrine tumors"],"catalyst":""},{"name":"nab-paclitaxel; gemcitabine","genericName":"nab-paclitaxel; gemcitabine","slug":"nab-paclitaxel-gemcitabine","phase":"phase_3","mechanism":"nab-paclitaxel and gemcitabine work together as a chemotherapy combination to disrupt microtubule dynamics and inhibit DNA synthesis, respectively, to kill rapidly dividing cancer cells.","indications":["Pancreatic cancer","Non-small cell lung cancer","Breast cancer"],"catalyst":""},{"name":"placebo+chemotherapy","genericName":"placebo+chemotherapy","slug":"placebo-chemotherapy","phase":"phase_3","mechanism":"This drug works by enhancing the effects of chemotherapy.","indications":["Metastatic breast cancer, Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"saline eye drops.","genericName":"saline eye drops.","slug":"saline-eye-drops","phase":"phase_3","mechanism":"Saline eye drops work by lubricating the eyes to help relieve dryness and irritation.","indications":["Dry eye syndrome","Eye irritation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMjBkbF80eFJWRDJhbFBYX25nTmp5ektGWXFldllYWGRqREVKWnJGVDJWMUR1TkQ1V2xOT3RmVHpDUXhRbEhlSS1ZR243bm9aVFRETk1reEY3NmNXYjVHS0RWcmVxYTJaN01wQ2hGNDBYNWIzWUxnQ3EyWGVtS3V2TUl0ZmhXVk85ZFpRRFJGZThYRDhOdnk1QkRkdDVpaG5FU3pVVXppeHVEUXVobWhNZGxYWUYyclVGWnJEUk5uVkpqeDQ?oc=5","date":"2026-03-25","type":"pipeline","source":"FinancialContent","summary":"Hengrui Pharma Announces Strong 2025 Annual Results - FinancialContent","headline":"Hengrui Pharma Announces Strong 2025 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOdWJEZHA1ZVp5SGJ6SmNoNmJZcndMbGhFckVJM2hJZUpxSjZoU1Y0QXViQWZNM3ZRY0t1UzlSVTJFejZLWHFFNm5JRHBZSGR0NWhUbWlwWF9hN0VrOEcwSmJkX0xlRGVEUVROTEVUckR3SVFtYUVGa2tKb3dodzZBeGpnRm90cGZ3MEVTaGFyNHQ2aUNENzVBZGxGR2MxT2lFU2RGY3VYZmhtWTNfdHcyWHh2RWJGeEMway1jaVBhSU9vMDRDMHRQV3Bzb3FLZWlTVHJsYm9SLXF3elhEek1uUXFZNA?oc=5","date":"2026-03-24","type":"pipeline","source":"marketscreener.com","summary":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shanghai Shengdi Private Equity Fund Management Co., Ltd., Shenzhen Yingtai Asset Manag","headline":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shangha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1lsTmVGYmFzSGkzRXlVX2RMeDI2UlQ0VVJBVkhYMkQ1VlpaMFNCX3gtdzBwZEU5UWtUbWNPWmxhMm5jQ3AyMWtMMXhkVW9RSlM2bTNzVy1SdUt6Vmp0Wjk3T0tvUGZHQktEc1B0aTBBbUNfelU4XzFoOHZWVEdrVFpNYklZbFZNQWFDUlFhbVFaaDdYVE03VlNvdk9VczhYY2Q2Ul9KX0F3c3RKQk1QZVQxa3BuOEJOMnQ2Q1lwc3hLYkc5UEtSWm1wTVNHMVpaQ2Y1SmQ3dGljYS1aWjNIWVotRUI1T1lTLUZMb3ROenV5T2ZPOVl5cnVBV19CbTNabnRhOGQzSXhhY1pDWnBXOGFabw?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPaTZTcHo3NXI4d1V3bHBkeUo3aTR0ZXd0Q0JFNC1VWEJFeGFzVS11cTlGRG5uS0h4S1JDNjlpVVdvaFpZcWtRQzVGNE1aMkEtLUZ0Mm53ZTFoX2NITTB4SDdwMlMtWFg3TFNoZ2ZEQWQxenB6ek5YcHJwdjdwNE1UUWV4M1BjdUtKclZ4T25kRTNTUEJwdjZBRXVza1k2Q2x0WE5EdldaR3RhbGdfRGVLSnQ1eEZrdnpLWHcxM2xObEk0YXhvNG5sakVodlpna29zVzRSYkdDTXNWZVR4S0xYckh6WUJwWlFoVkNV?oc=5","date":"2026-03-03","type":"pipeline","source":"The Globe and Mail","summary":"Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED - The Globe and Mail","headline":"Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOZ1llTFI5SGdCSTJtX2Z0M0ZXaXFZQXNOaFRLUnhaV3g5aFp4V3RCa0Z2T0J6eHUtS3JRMmxDdG9qMUxUb1d0b0VBOGpKSUczUzJSZUtWalRqckk3UUpxdEo2aXplY3MzZlpMaVRXc0g3TzdPSVlwcEJDNDRhTm9kak1wUVh3ZGdBM2lKd19TNmJTekNsOHVoNUhmNjd0VnV0NllkRg?oc=5","date":"2026-01-29","type":"patent","source":"BioWorld News","summary":"Hengrui Pharmaceuticals patent reports Nav1.8 channel blockers - BioWorld News","headline":"Hengrui Pharmaceuticals patent reports Nav1.8 channel blockers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1IdUduYW94WjViV25oeldEdEpycExJeERLRHZKZnFqLUI4MjRVS19iNUQ0OGNTcmd6QmxPWmhiUktoSWUxZUNhMmIzaGo3eU9jNURJbXducVRKWmNDUjAycncxbTVKWHFRRUhfUUNmRnNoS2QtTkFBVVkyRk5JZw?oc=5","date":"2025-12-26","type":"pipeline","source":"China Daily","summary":"Pharma innovations gain traction abroad - China Daily","headline":"Pharma innovations gain traction abroad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQbTc3eTdzcUk4cWpqTkd3ZjZjR21vR3ZXYmwwMm5qUl8yMnBFT1REMlVHZ0YtYWMyWjE5elZYTjNzNmVXQUtQdUJfOFktSGJrUk1xdDhrZk92MXc5QW56YWxaWDZNYzlWaFVVNGNjMmVWMVpwRE5yd282eUVmcEJ3c25BTXFhSktjYVVMRGRRTUtzd2dOd3pBNV8tcUdHb2JxWHZjczZsSzFJZTZG?oc=5","date":"2025-11-29","type":"earnings","source":"Statista","summary":"Annual revenue of Jiangsu Hengrui Pharmaceuticals 2015-2024 - Statista","headline":"Annual revenue of Jiangsu Hengrui Pharmaceuticals 2015-2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9hYTFTcmJWblhkS05GTXJEaHFQMUlrUDNXYTRyWHREVVBTUEJLLUZXSF8tNUJ3cGNLNnFyc3kwV2hxZkFZMExiSHV4SUIyOThyYVR4S0dpdjdkUzZHT3NnNVkyRUlLTy1KOWdfRnRrVDRhRWZyektHQTRyel9EZw?oc=5","date":"2025-11-20","type":"pipeline","source":"pharmaphorum","summary":"The importance of globalisation for patient access - pharmaphorum","headline":"The importance of globalisation for patient access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5","date":"2025-07-28","type":"deal","source":"Reuters","summary":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal - Reuters","headline":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPandkMnQwNEl6TFNNWFJPMFF6Z3c4MlFzbEZKUnQwbnpUYm91eFQtSGVYMDN1MS1xMXJLdGpWckIweGM1bEl0S0ZQRXU4UkY2VTFrWERkNjBYN1VrcjkzVGMxbHBmWV9QZ2NOZW5pUE42LVlRX0Jpa0xrT2FCLWllU1BCVV8wSmd6ZzdnZmJuNlU?oc=5","date":"2025-07-28","type":"pipeline","source":"GSK","summary":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology - GSK","headline":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1cta19lTmdVSkppd3h2MjRpd3BNZW82M0VqMU5QUGtvckpzak5ydE9hVE5sZnBOOUJTejQ5QjZtUG45NFNvNU9Dd0ZkVnNXZmJFcDdNbW1nSXVNU1Y3S2xiSHpodHdlZDFNTHdoTXYtRXRLU2FDTWNwbVpTZG1oRl9pS2o3eHU5c2ZTd0l3cjdTSnhGRkFqZUVpLVNxQ3h1MnlVV1h5eGI?oc=5","date":"2025-07-28","type":"deal","source":"Bloomberg.com","summary":"Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion - Bloomberg.com","headline":"Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQR01VWktIR2toXzg2aF85S1VEVk5xOXVxM3k4VEVka01iaWRQVzZOSHF4aFVfVmdYcnpKMmVuY05rS3BkWUJrb05ORXM4SGpJeEVxMkt0S0h4S0VSTFkyMTYwVkxCVmNGSG5xd2NDLXdMZHZaNkpxT2pidHNiUkNkb25lamd0dGlELV9xTVo0RkRDUVZMWldQQ2JzWWkxSzdLOVRRMEJLMWpjYVhKb05QdzJ3UnA?oc=5","date":"2025-05-23","type":"pipeline","source":"Cleary Gottlieb","summary":"Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO - Cleary Gottlieb","headline":"Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO","sentiment":"neutral"}],"patents":[],"drugCount":95,"phaseCounts":{"marketed":5,"phase_3":60,"phase_1":11,"phase_2":17,"discontinued":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}